Overview
I see patients with chronic liver diseases. I have a clinical and research interest in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Areas of interest include identifying patients at high risk for NAFLD/NASH, developing care pathways to specialty care and creating sustainable multidisciplinary and lifestyle programs for people impacted with NAFLD/NASH.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Gastroenterology,
Medicine
Recent Publications
Leveraging an Electronic Consultation Program for a High-Volume Hepatology Clinic.
Journal Article Clin Transl Gastroenterol · April 8, 2026 INTRODUCTION: The prevalence of chronic liver disease is increasing in the United States, and a concurrent national shortage of hepatologists has resulted in long wait times for specialty care. Electronic consultations (E-consults) have emerged as a strate ... Full text Link to item CiteChange in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis.
Journal Article Clin Gastroenterol Hepatol · February 2026 BACKGROUND & AIMS: Liver corrected T1 (cT1), measured with multiparametric magnetic resonance imaging, offers an alternative to liver biopsy to monitor treatment response and liver disease activity. We aimed to perform a systematic evaluation of change in ... Full text Link to item CiteThe Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment.
Journal Article J Am Coll Cardiol · November 18, 2025 Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as a multisystem disease closely linked to cardiovascular disease, which is the leading cause of death in this population. MASLD and cardiovascular disease share overlapping ... Full text Link to item CiteRecent Grants
BIO89-100-132 The ENLIGHTEN-Cirrhosis Pro00116849
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2031ZENITH-1 Protocol number: 301160 Protocol tile: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunct
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2026 - 2030ZENITH-2 Protocol number: 306246 Protocol title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic D
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2026 - 2030View All Grants
Education
American University of the Caribbean ·
2005
M.D.